Ertapenem
- Generic Name
- Ertapenem
- Brand Names
- Invanz, Ertapenem SUN
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25N3O7S
- CAS Number
- 153832-46-3
- Unique Ingredient Identifier
- G32F6EID2H
- Background
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to treat various bacterial infections.
- Indication
Ertapenem is indicated to treat the following moderate to severe infections caused by susceptible bacteria in adult and pediatric patients (three months of age and older):
Ertapenem is also used in adults for the prophylaxis of surgical site infection following elective colorectal surgery.
- Associated Conditions
- Acute Gynecological Infection, Severe Community-acquired Pneumonia (sCAP), Surgical Site Infections, Acute, moderate Pelvic Infections caused by susceptible bacteria, Acute, severe susceptible bacteria Pelvic Infections, Moderate Community acquired pneumonia, Moderate Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Moderate Diabetic Foot Infection, Moderate Gynaecological infection caused by susceptible bacteria, Moderate Postpartum Endomyometritis caused by susceptible bacteria, Moderate Septic Abortion caused by susceptible bacteria, Moderate complicated Urinary Tract Infection caused by susceptible bacteria, Moderate complicated skin and skin-structure infections caused by susceptible bacteria, Severe Complicated Intra-Abdominal Infections (cIAIs) caused by susceptible bacteria, Severe Diabetic Foot Infection, Severe Gynaecological infection caused by susceptible bacteria, Severe Postpartum Endomyometritis caused by susceptible bacteria, Severe Septic Abortion caused by susceptible bacteria, Severe complicated Urinary Tract Infection caused by susceptible bacteria, Severe complicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
Prospective, Open-label Study of Pharmacokinetics of Ertapenem in the Muscle Using Microdialysis in Mechanically Ventilated Intensive Care Unit Patients, Treated or Not by Norepinephrine
- Conditions
- Interventions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 9
- Registration Number
- NCT00489138
- Locations
- 🇫🇷
Département d'Anesthésie-Réanimation - CHU NORD, Marseille, France
Penetration of Ertapenem Into Bone
- Conditions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2007-07-13
- Lead Sponsor
- HaEmek Medical Center, Israel
- Target Recruit Count
- 12
- Registration Number
- NCT00392028
- Locations
- 🇮🇱
Ha'Emek Medical Center, Afula, Israel
🇮🇱Haemek Medical Center INFECTIOUS DISEASES UNIT, Afula, Israel
A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT00379951
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
- Conditions
- Interventions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 1061
- Registration Number
- NCT00366249
Study to Evaluate the Duration of Treatment With Ertapenem in Acute Attacks of Sigmoid Diverticulitis
- Conditions
- First Posted Date
- 2004-11-30
- Last Posted Date
- 2006-02-14
- Lead Sponsor
- Klinikum Hanover-Siloah Hospital
- Target Recruit Count
- 540
- Registration Number
- NCT00097734
- Locations
- 🇩🇪
Klinikum Hannover- Krankenhaus Siloah, Hannover, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.